NGHIÊN CỨU TÁC DỤNG CHỐNG ĐÔNG MÁU CỦA CỐM THARODAS TRÊN ĐỘNG VẬT THỰC NGHIỆM

Abstract

Research objective: To study on the anticoagulant effect of Tharodas granules on a mice model induced by lipopolysaccharide. Subjects and methods: Swiss white mice, both breeds, healthy, weighing 30g - 35g that were provided by the National Institute of Hygiene and Epidemiology. Research method: Research on the anticoagulant effect of Tharodas granules on the lipopolysaccharide coagulation model by Wang B et al. Result: Tharodas granules at a dose of 1.44 g/kg/day tend to be anticoagulant in the lipopolysaccharide coagulation model through preventing platelet aggregation. Tharodas granules at a dose of 4.32 g/kg/day (triple dose) has an anticoagulant effect on the lipopolysaccharide coagulation model through preventing platelet aggregation, equivalent to Rivaroxaban at a dose of 10 mg/kg/day. Tharodas granules at a dose of 4.32 g/kg/day tend to prevent the process of prothrombin from converting into thrombin and the process of consuming exogenously active coagulation factors better (not statistically significant) compared to Rivaroxaban dose 10 mg/kg/day. However, these trends were not better than those at the 1.44 g/kg/day dose. Conclusion: Tharodas granules at a dose of 4.32 g/kg/day (3 times the expected dose for clinical effect) has an anticoagulant effect on the lipopolysaccharide coagulation model through preventing platelet aggregation, equivalent to Rivaroxaban. dose 10 mg/kg/day.